Consequently, BTK has been developed into an effective therapeutic target upstream of IKK in various types of B-cell malignancy, including chronic lymphocytic leukaemia (CLL), mantle-cell lymphoma (MCL), follicular lymphoma (FL), DLBCL and acute lymphoblastic leukaemia (ALL) [113]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.